|Exclusion Criteria:||1) Receipt of glucocorticoids (with the exception of inhaled glucocorticoid steroids for the use of allergic rhinitis or pulmonary disease) within 2 months prior to registration.|
2) History of autoimmune disease unrelated to CLL (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis). Autoimmune disease related to CLL, e.g. idiopathic thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia, is permitted if not requiring active treatment.
3) Subject Recruitment and Accrual Accrual is anticipated to take 12-15 months at a recruitment rate of approximately 1 patient per site per month. The expectation is that each site will recruit 50% of the target of 20 total evaluable patients. Subjects will be identified through the clinical practices of the investigator or sub investigators in the Division of Stem Cell Transplantation and Cell Therapy at MD Anderson and Division of Hematology-Oncology at both MD Anderson and UPENN.